Effect of antagonists of dopamine and opiates on the basal and GnRH-induced secretion of luteinizing hormone, follicle stimulating hormone and prolactin during lactational amenorrhoea in breastfeeding women.
The role of dopamine and opiates in the suckling-induced suppression of gonadotrophin secretion and prolactin release was investigated during lactational amenorrhoea in fully breastfeeding women at 12 weeks post-partum. A total of 26 women, 20 using non-steroidal methods of contraception and six using the progestogen-only pill, Noriday (POP), breastfed their babies on demand at a frequency of 3.6 +/- 0.2 suckling episodes during the 8 h study period while blood samples were collected at 10-min intervals. Five hours after the start of sampling six women were given the dopamine antagonist metoclopramide (10 mg, i.m.) while four women received saline. In a second experiment, six women using nonsteroidal contraception and three women on the POP received an i.v. infusion of the opiate antagonist naloxone (1.6 mg/h) for 2 h, while four women using non-steroidal contraception and three women on the POP were infused with saline. Two hours after the i.m. injection or start of infusion all women were given an i.v. injection of 10 micrograms gonadotrophin releasing hormone (GnRH) and samples were collected for a further 1 h. All samples were assayed for luteinizing hormone (LH), follicle stimulating hormone (FSH) and prolactin. Plasma concentrations of oestradiol were < 60 pmol/l in all women and they remained amenorrhoeic for at least 10 weeks after the study. Pulsatile release of LH was only observed over the 5 h pre-treatment period in 10 of the 20 non-steroid taking women (1-3 pulses/5 h), and in one of the six women (1 pulse/5 h) on POP.(ABSTRACT TRUNCATED AT 250 WORDS)
Tay
C C
CC
Department of Obstetrics and Gynaecology, University of Edinburgh, Centre for Reproductive Biology, UK.
Glasier
A F
AF
McNeilly
A S
AS
D000568:Amenorrhea / Q000503:physiopathology*; D001942:Breast Feeding; D004298:Dopamine / Q000502:physiology; D018492:Dopamine Antagonists; D004723:Endorphins / Q000502:physiology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology*; D006062:Gonadotropins / Q000378:metabolism*; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism; D008787:Metoclopramide / Q000494:pharmacology*; D009270:Naloxone / Q000494:pharmacology*; D049590:Postpartum Period / Q000502:physiology*; D011388:Prolactin / Q000378:metabolism; D012636:Secretory Rate / Q000187:drug effects
D018492:Dopamine Antagonists; D004723:Endorphins; D006062:Gonadotropins; D007987:Gonadotropin-Releasing Hormone; D009270:Naloxone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008787:Metoclopramide; D004298:Dopamine